This HTML5 document contains 189 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n11http://linked.opendata.cz/resource/drugbank/drug/DB01114/identifier/bindingdb/
n7http://linked.opendata.cz/resource/drugbank/drug/DB01114/identifier/kegg-compound/
n21http://linked.opendata.cz/resource/AHFS/
n19http://linked.opendata.cz/resource/mesh/concept/
foafhttp://xmlns.com/foaf/0.1/
n15http://linked.opendata.cz/resource/drugbank/company/
n32http://linked.opendata.cz/resource/drugbank/drug/DB01114/identifier/pubchem-compound/
n14http://linked.opendata.cz/resource/drugbank/dosage/
n22http://linked.opendata.cz/resource/drugbank/mixture/
n33http://linked.opendata.cz/resource/drugbank/drug/DB01114/identifier/kegg-drug/
n30http://linked.opendata.cz/resource/drugbank/drug/DB01114/identifier/pubchem-substance/
n10http://linked.opendata.cz/resource/drugbank/drug/DB01114/identifier/drugbank/
n4http://linked.opendata.cz/resource/drugbank/drug/DB01114/identifier/iuphar/
n25http://bio2rdf.org/drugbank:
n8http://linked.opendata.cz/resource/drugbank/drug/DB01114/identifier/guide-to-pharmacology/
n34http://linked.opendata.cz/resource/drugbank/drug/DB01114/identifier/national-drug-code-directory/
admshttp://www.w3.org/ns/adms#
n27http://www.rxlist.com/cgi/generic/
n17http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n13http://linked.opendata.cz/resource/drugbank/medicinal-product/
n9http://linked.opendata.cz/resource/drugbank/drug/DB01114/identifier/chemspider/
owlhttp://www.w3.org/2002/07/owl#
n18http://linked.opendata.cz/ontology/mesh/
n5http://linked.opendata.cz/ontology/drugbank/
n28http://www.drugs.com/cdi/
n12http://linked.opendata.cz/resource/drugbank/drug/DB01114/identifier/chebi/
n6http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n31http://linked.opendata.cz/resource/drugbank/drug/DB01114/identifier/pharmgkb/
n23http://linked.opendata.cz/resource/drugbank/drug/DB01114/identifier/wikipedia/
n29http://linked.opendata.cz/resource/atc/
n20http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB01114
rdf:type
n5:Drug
n5:description
A histamine H1 antagonist used in allergic reactions, hay fever, rhinitis, urticaria, and asthma. It has also been used in veterinary applications. One of the most widely used of the classical antihistaminics, it generally causes less drowsiness and sedation than promethazine. [PubChem]
n5:dosage
n14:271B4290-363D-11E5-9242-09173F13E4C5 n14:271B428D-363D-11E5-9242-09173F13E4C5 n14:271B428E-363D-11E5-9242-09173F13E4C5 n14:271B428F-363D-11E5-9242-09173F13E4C5
n5:generalReferences
* "MSDS":http://msds.orica.com/pdf/shess-en-cds-010-000000033835.pdf
n5:group
approved
n5:halfLife
21-27 hours
n5:indication
For the treatment of rhinitis, urticaria, allergy, common cold, asthma and hay fever.
owl:sameAs
n17:DB01114 n25:DB01114
dcterms:title
Chlorphenamine
adms:identifier
n4:1213 n7:C06905 n8:1213 n9:2624 n10:DB01114 n11:35938 n12:52010 n23:Chlorpheniramine n30:46508253 n31:PA448960 n32:2725 n33:D07398 n34:60432-539-04
n5:mechanismOfAction
Chlorpheniramine binds to the histamine H1 receptor. This blocks the action of endogenous histamine, which subsequently leads to temporary relief of the negative symptoms brought on by histamine.
n5:packager
n15:271B4262-363D-11E5-9242-09173F13E4C5 n15:271B4263-363D-11E5-9242-09173F13E4C5 n15:271B4261-363D-11E5-9242-09173F13E4C5 n15:271B4266-363D-11E5-9242-09173F13E4C5 n15:271B4267-363D-11E5-9242-09173F13E4C5 n15:271B4264-363D-11E5-9242-09173F13E4C5 n15:271B4265-363D-11E5-9242-09173F13E4C5 n15:271B426C-363D-11E5-9242-09173F13E4C5 n15:271B426D-363D-11E5-9242-09173F13E4C5 n15:271B4268-363D-11E5-9242-09173F13E4C5 n15:271B426B-363D-11E5-9242-09173F13E4C5 n15:271B426A-363D-11E5-9242-09173F13E4C5 n15:271B4271-363D-11E5-9242-09173F13E4C5 n15:271B4260-363D-11E5-9242-09173F13E4C5 n15:271B4269-363D-11E5-9242-09173F13E4C5 n15:271B4276-363D-11E5-9242-09173F13E4C5 n15:271B427C-363D-11E5-9242-09173F13E4C5 n15:271B4272-363D-11E5-9242-09173F13E4C5 n15:271B4273-363D-11E5-9242-09173F13E4C5 n15:271B427D-363D-11E5-9242-09173F13E4C5 n15:271B427E-363D-11E5-9242-09173F13E4C5 n15:271B425E-363D-11E5-9242-09173F13E4C5 n15:271B425F-363D-11E5-9242-09173F13E4C5 n15:271B4282-363D-11E5-9242-09173F13E4C5 n15:271B4283-363D-11E5-9242-09173F13E4C5 n15:271B425D-363D-11E5-9242-09173F13E4C5 n15:271B4281-363D-11E5-9242-09173F13E4C5 n15:271B4278-363D-11E5-9242-09173F13E4C5 n15:271B4279-363D-11E5-9242-09173F13E4C5 n15:271B4275-363D-11E5-9242-09173F13E4C5 n15:271B4277-363D-11E5-9242-09173F13E4C5 n15:271B427F-363D-11E5-9242-09173F13E4C5 n15:271B4258-363D-11E5-9242-09173F13E4C5 n15:271B4280-363D-11E5-9242-09173F13E4C5 n15:271B427A-363D-11E5-9242-09173F13E4C5 n15:271B427B-363D-11E5-9242-09173F13E4C5 n15:271B425B-363D-11E5-9242-09173F13E4C5 n15:271B425C-363D-11E5-9242-09173F13E4C5 n15:271B4259-363D-11E5-9242-09173F13E4C5 n15:271B425A-363D-11E5-9242-09173F13E4C5 n15:271B4270-363D-11E5-9242-09173F13E4C5 n15:271B4274-363D-11E5-9242-09173F13E4C5 n15:271B426F-363D-11E5-9242-09173F13E4C5 n15:271B426E-363D-11E5-9242-09173F13E4C5
n5:synonym
Chlorpheniraminum gamma-(4-Chlorophenyl)-N,N-dimethyl-2-pyridinepropanamine Clofeniramina γ-(4-chlorophenyl)-γ-(2-pyridyl)propyldimethylamine 2-[P-chloro-alpha-[2-(dimethylamino)Ethyl]benzyl]pyridine Haynon 3-(P-Chlorophenyl)-3-(2-pyridyl)-N,N-dimethylpropylamine Chlorphenamin Chlorophenylpyridamine 1-(p-chlorophenyl)-1-(2-pyridyl)-3-dimethylaminopropane Clorfenamina Chlorphenamine gamma-(4-Chlorophenyl)-gamma-(2-pyridyl)propyldimethylamine 1-(P-Chlorophenyl)-1-(2-pyridyl)-3-N,N-dimethylpropylamine Chlorphenaminum Clorfeniramina Chlorpheniramine
n5:toxicity
Oral LD50 (rat): 306 mg/kg; Oral LD50 (mice): 130 mg/kg; Oral LD50 (guinea pig): 198 mg/kg [Registry of Toxic Effects of Chemical Substances. Ed. D. Sweet, US Dept. of Health & Human Services: Cincinatti, 2010.] Also a mild reproductive toxin to women of childbearing age.
n20:hasAHFSCode
n21:04-04-20
n5:foodInteraction
Avoid alcohol. Take with food.
n5:mixture
n22:271B4256-363D-11E5-9242-09173F13E4C5 n22:271B4257-363D-11E5-9242-09173F13E4C5 n22:271B4254-363D-11E5-9242-09173F13E4C5 n22:271B4255-363D-11E5-9242-09173F13E4C5 n22:271B4252-363D-11E5-9242-09173F13E4C5 n22:271B4253-363D-11E5-9242-09173F13E4C5 n22:271B4250-363D-11E5-9242-09173F13E4C5 n22:271B4251-363D-11E5-9242-09173F13E4C5 n22:271B424E-363D-11E5-9242-09173F13E4C5 n22:271B424F-363D-11E5-9242-09173F13E4C5 n22:271B424C-363D-11E5-9242-09173F13E4C5 n22:271B424D-363D-11E5-9242-09173F13E4C5 n22:271B424A-363D-11E5-9242-09173F13E4C5 n22:271B424B-363D-11E5-9242-09173F13E4C5 n22:271B4247-363D-11E5-9242-09173F13E4C5 n22:271B4249-363D-11E5-9242-09173F13E4C5 n22:271B4245-363D-11E5-9242-09173F13E4C5 n22:271B4246-363D-11E5-9242-09173F13E4C5 n22:271B4243-363D-11E5-9242-09173F13E4C5 n22:271B4244-363D-11E5-9242-09173F13E4C5 n22:271B4241-363D-11E5-9242-09173F13E4C5 n22:271B4242-363D-11E5-9242-09173F13E4C5 n22:271B423F-363D-11E5-9242-09173F13E4C5 n22:271B4240-363D-11E5-9242-09173F13E4C5 n22:271B423B-363D-11E5-9242-09173F13E4C5 n22:271B423E-363D-11E5-9242-09173F13E4C5 n22:271B4239-363D-11E5-9242-09173F13E4C5 n22:271B423A-363D-11E5-9242-09173F13E4C5 n22:271B4237-363D-11E5-9242-09173F13E4C5 n22:271B4238-363D-11E5-9242-09173F13E4C5 n22:271B4235-363D-11E5-9242-09173F13E4C5 n22:271B4236-363D-11E5-9242-09173F13E4C5 n22:271B4233-363D-11E5-9242-09173F13E4C5 n22:271B4234-363D-11E5-9242-09173F13E4C5 n22:271B4231-363D-11E5-9242-09173F13E4C5 n22:271B4232-363D-11E5-9242-09173F13E4C5 n22:271B422F-363D-11E5-9242-09173F13E4C5 n22:271B4230-363D-11E5-9242-09173F13E4C5 n22:271B422D-363D-11E5-9242-09173F13E4C5 n22:271B422E-363D-11E5-9242-09173F13E4C5 n22:271B422B-363D-11E5-9242-09173F13E4C5 n22:271B422C-363D-11E5-9242-09173F13E4C5 n22:271B4229-363D-11E5-9242-09173F13E4C5 n22:271B422A-363D-11E5-9242-09173F13E4C5 n22:271B4228-363D-11E5-9242-09173F13E4C5 n22:271B423C-363D-11E5-9242-09173F13E4C5 n22:271B423D-363D-11E5-9242-09173F13E4C5 n22:271B4248-363D-11E5-9242-09173F13E4C5
n5:proteinBinding
72%
n5:salt
n5:synthesisReference
Anil M. Salpekar, John Johnson, "Acetaminophen compositions containing low doses of chlorpheniramine maleate, method for preparing same and tablets formed therefrom." U.S. Patent US4631284, issued April, 1975.
n18:hasConcept
n19:M0004190
foaf:page
n27:chlorpheniramine.htm n28:chlorpheniramine.html
n5:IUPAC-Name
n6:271B4295-363D-11E5-9242-09173F13E4C5
n5:InChI
n6:271B429B-363D-11E5-9242-09173F13E4C5
n5:Molecular-Formula
n6:271B429A-363D-11E5-9242-09173F13E4C5
n5:Molecular-Weight
n6:271B4297-363D-11E5-9242-09173F13E4C5
n5:Monoisotopic-Weight
n6:271B4298-363D-11E5-9242-09173F13E4C5
n5:SMILES
n6:271B4299-363D-11E5-9242-09173F13E4C5
n5:Water-Solubility
n6:271B4293-363D-11E5-9242-09173F13E4C5 n6:271B42AA-363D-11E5-9242-09173F13E4C5
n5:logP
n6:271B4291-363D-11E5-9242-09173F13E4C5 n6:271B4294-363D-11E5-9242-09173F13E4C5 n6:271B42AC-363D-11E5-9242-09173F13E4C5
n5:logS
n6:271B4292-363D-11E5-9242-09173F13E4C5
n5:pKa
n6:271B42AD-363D-11E5-9242-09173F13E4C5
n20:hasATCCode
n29:R06AB04
n5:H-Bond-Acceptor-Count
n6:271B42A1-363D-11E5-9242-09173F13E4C5
n5:H-Bond-Donor-Count
n6:271B42A2-363D-11E5-9242-09173F13E4C5
n5:InChIKey
n6:271B429C-363D-11E5-9242-09173F13E4C5
n5:Polar-Surface-Area--PSA-
n6:271B429D-363D-11E5-9242-09173F13E4C5
n5:Polarizability
n6:271B429F-363D-11E5-9242-09173F13E4C5
n5:Refractivity
n6:271B429E-363D-11E5-9242-09173F13E4C5
n5:Rotatable-Bond-Count
n6:271B42A0-363D-11E5-9242-09173F13E4C5
n5:absorption
Well absorbed in the gastrointestinal tract.
n5:affectedOrganism
Humans and other mammals
n5:casRegistryNumber
132-22-9
n5:category
n5:containedIn
n13:271B4284-363D-11E5-9242-09173F13E4C5 n13:271B4287-363D-11E5-9242-09173F13E4C5 n13:271B4288-363D-11E5-9242-09173F13E4C5 n13:271B428B-363D-11E5-9242-09173F13E4C5 n13:271B428C-363D-11E5-9242-09173F13E4C5 n13:271B4289-363D-11E5-9242-09173F13E4C5 n13:271B428A-363D-11E5-9242-09173F13E4C5 n13:271B4285-363D-11E5-9242-09173F13E4C5 n13:271B4286-363D-11E5-9242-09173F13E4C5
n5:Bioavailability
n6:271B42A6-363D-11E5-9242-09173F13E4C5
n5:Boiling-Point
n6:271B42AB-363D-11E5-9242-09173F13E4C5
n5:Ghose-Filter
n6:271B42A8-363D-11E5-9242-09173F13E4C5
n5:MDDR-Like-Rule
n6:271B42A9-363D-11E5-9242-09173F13E4C5
n5:Number-of-Rings
n6:271B42A5-363D-11E5-9242-09173F13E4C5
n5:Physiological-Charge
n6:271B42A4-363D-11E5-9242-09173F13E4C5
n5:Rule-of-Five
n6:271B42A7-363D-11E5-9242-09173F13E4C5
n5:Traditional-IUPAC-Name
n6:271B4296-363D-11E5-9242-09173F13E4C5
n5:pKa--strongest-basic-
n6:271B42A3-363D-11E5-9242-09173F13E4C5